tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Karl Chalabala, 7 are a BUY (87.5%), 1 are a HOLD (12.5%).
Analyst Karl Chalabala, currently employed at UBS, carries an average stock price target met ratio of 33.33% that have a potential upside of 14.65% achieved within 604 days. Previously, Karl Chalabala worked at STIFEL.
Karl Chalabala’s has documented 12 price targets and ratings displayed on 3 stocks. The coverage is on Energy, Healthcare sectors.
Most recent stock forecast was given on FOLD, Amicus Therapeutics at 10-May-2024.
Analyst best performing recommendations are on EQT (EQT).
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$63
$4.69 (8.04%)
$58
17 days ago
(16-Jun-2025)
8/9 (88.89%)
$4.83 (8.30%)
165
Hold
$48
$-10.31 (-17.68%)
$35
1 months 20 days ago
(13-May-2025)
15/22 (68.18%)
$-8.2 (-14.59%)
582
Hold
$64
$5.69 (9.76%)
$54
1 months 28 days ago
(05-May-2025)
9/10 (90%)
$10.48 (19.58%)
140
Buy
$65
$6.69 (11.47%)
$67
2 months 9 days ago
(24-Apr-2025)
17/19 (89.47%)
$16.18 (33.14%)
153
Buy
$60
$1.69 (2.90%)
3 months 2 days ago
(01-Apr-2025)
15/17 (88.24%)
$6.12 (11.36%)
303
What Year was the first public recommendation made by Karl Chalabala?
